Terkko Navigator / Annals of the rheumatic diseases

'Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients

Response to: 'Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients by Buch et al

DAPSA versus cDAPSA: Do we need to use CRP?

Treat to target in PsA should focus on clinical measures. Response to: 'DAPSA versus cDAPSA: do we need to use CRP? by Goncalves et al

Less antibiotics but no inferior effect for bacterial arthritis

Response to: 'Less antibiotics but no inferior effect for bacterial arthritis by Zhang et al

Is it currently reasonable to offer short, 14-day antibiotic therapies after a surgical synovectomy in native joint septic arthritis?

Response to: 'Is it currently reasonable to offer short 14-day antibiotic therapies after a surgical synovectomy in native joint septic arthritis? by Coiffier et al

Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter

Response to: 'Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter by Sbeih et al

Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations

Response to: 'Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations by Orsolini et al

Semiquantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?

Response to: 'Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance? by Cavazzana et al

Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?

Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis

EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis

Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response

Contrasting contributions of TNF from distinct cellular sources in arthritis

Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study

Salivary gland epithelial cells from patients with Sjögrens syndrome induce B-lymphocyte survival and activation

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging

Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1{beta} activation on macrophages

Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?

Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive

A pilot study of tofacitinib for refractory Behcets syndrome

Standardisation of PR3-ANCA and MPO-ANCA: evaluation of certified reference materials

Immune phenotyping of Erdheim-Chester disease through mass cytometry highlights decreased proportion of non-classical monocytes and increased proportion of Th17 cells

Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials

Response to: 'Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials by Lee and Song

Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA

Mortality has improved in RA, but we must remain vigilant. Response to: 'Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA by Matthijssen et al

Comment on editorial 'Pathogenic effector functions of ACPA: where do we stand?

Response to: 'Comment on editorial 'Pathogenic effector functions of ACPA: where do we stand by Holmdahl

On using machine learning algorithms to define clinically meaningful patient subgroups

On how to not misuse hierarchical clustering on principal components to define clinically meaningful patient subgroups. Response to: 'On using machine learning algorithms to define clinical meaningful patient subgroups by Pinal-Fernandez and Mammen

Response to: 'On using machine learning algorithms to define clinically meaningful patient subgroups by Pinal-Fernandez and Mammen

Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Response to: 'Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Rua-Figueroa and Erausquin

Treatment of systemic lupus erythematosus: dont forget hydroxychloroquine

Response to: 'Treatment of systemic lupus erythematosus: dont forget hydroxychloroquine by Michaud et al

Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome

Response to: 'Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome by van den Hoogen et al